What: Shares of Lion Biotechnologies (NASDAQ: LBIO), a clinical-stage biotech focused on cancer immunotherapy, leapt by more than 25% as of 12:00 p.m. EDT after the company announced that it has appointed a new CEO and raised money through a private offering.